When producing a biosimilar – a generic version of an original biotherapeutic reference product (innovator) – both biological potency, safety, and efficacy must be assessed during the analysis process. This is especially important for quality assurance purposes and to obtain approval from regulatory agencies, e.g. FDA/EMA.